Scarica l'app Stockscreener
6.31
0.48%
0.03
Pre-mercato:
6.42
0.11
+1.74%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AURA Giù?
Forum
Previsione
Precedente Chiudi:
$6.28
Aprire:
$6.25
Volume 24 ore:
531.09K
Relative Volume:
1.05
Capitalizzazione di mercato:
$652.37M
Reddito:
-
Utile/perdita netta:
$-112.39M
Rapporto P/E:
-3.5785
EPS:
-1.7633
Flusso di cassa netto:
$-91.64M
1 W Prestazione:
+3.10%
1M Prestazione:
-18.48%
6M Prestazione:
+7.86%
1 anno Prestazione:
+2.10%
Intervallo 1D:
$6.25
$6.641
Intervallo di 1 settimana:
$6.03
$6.641
Portata 52W:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Nome
Aura Biosciences Inc
Settore
Industria
Telefono
(617)500-8864
Indirizzo
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.31 | 666.84M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-26 | Ripresa | Evercore ISI | Outperform |
| 2025-05-28 | Ripresa | H.C. Wainwright | Buy |
| 2024-07-25 | Iniziato | H.C. Wainwright | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-04-17 | Ripresa | BTIG Research | Buy |
| 2022-07-19 | Iniziato | JMP Securities | Mkt Outperform |
Mostra tutto
Aura Biosciences Inc Borsa (AURA) Ultime notizie
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options - Stock Titan
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options - Stock Titan
Aura Biosciences (AURA) director receives RSUs and stock options - Stock Titan
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options - Stock Titan
Technical Reactions to AURA Trends in Macro Strategies - Stock Traders Daily
Aura Biosciences (AURA) Gains 3% as Shares Bounce from SupportNHNL Ratio - newsline.com
Aura Biosciences, Inc. 8-K Filing Details for June 11, 2026: Emerging Growth Status and Shareholder Vote Submission 1821 – Minichart - Minichart
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com - Investing.com
Aura Biosciences Announces Results of 2026 Annual Meeting - TipRanks
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor - Stock Titan
Aura Biosciences Inc. Q1 2026 Earnings: Wider-than-Expected Loss Marks Early-Stage Pipeline Progress - newsline.com
Aura Biosciences gears up for Bel-Sar filing as pivotal eye cancer trial advances - MSN
Trading the Move, Not the Narrative: (AURA) Edition - Stock Traders Daily
Aura Biosciences highlights Bel-Sar eye cancer strategy, mid-year bladder data - MSN
Aura Biosciences completes phase 3 enrollment for eye cancer drug By Investing.com - Investing.com India
AURA Technical Analysis & Stock Price Forecast - Intellectia AI
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - The Manila Times
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment - Pluang
Aura Biosciences completes phase 3 enrollment for eye cancer drug - Investing.com
Eye cancer trial hits 108 patients as Aura tests new frontline therapy - Stock Titan
AURA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelinePost-Announcement Reaction - The Legal Advocate
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA) - ChartMill
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances - TradingView
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway - TradingView
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Ken Fisher's Aura Biosciences Inc(AURA) Holding History - GuruFocus
(AURA) Volatility Zones as Tactical Triggers - Stock Traders Daily
AURA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.4% on Pre-Clinical ProgressBalance Sheet Strength - Newser
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
AURA Director Holles Acquires 2.17M Stock Options on May 20, 2026 - Meyka
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data - inkl
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules. - Pluang
Aura Biosciences Grants Inducement Equity Awards to New CEO Natalie Holles - Quiver Quantitative
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles - Stock Titan
New Aura Biosciences CEO awarded options on 2.17M shares at $7.39 - Stock Titan
AURA: Bel-sar shows promise for vision-preserving cancer therapy, with pivotal data expected soon - TradingView
Wall Street analysts predict a 201.49% upside in Aura Biosciences (AURA): Here's what you should know - MSN
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
TradingKey - TradingKey
AURA Stock Price and Chart — NASDAQ:AURA - TradingView
Chen Yu and TCG Crossover report combined 9.9% stake in Aura Biosciences (AURA) - Stock Titan
Aura Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Leerink Partners Maintains Aura Biosciences(AURA.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Major Investor Makes Dramatic Exit from Aura Biosciences - TipRanks
Aura Biosciences reports Q1 results, appoints new CEO - TipRanks
Aura Biosciences (NASDAQ: AURA) posts higher Q1 loss but extends cash runway - Stock Titan
Matrix Capital fund exits 6.9M Aura Biosciences (AURA) shares in open-market sale - Stock Titan
Matrix Capital exits Aura Biosciences (AURA) after 6.9M-share, $5.64 repurchase - Stock Titan
Aura Biosciences Q1 net loss widens on higher R&D costs - TradingView
Aura Biosciences Inc Azioni (AURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aura Biosciences Inc Azioni (AURA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks |
Jun 16 '26 |
Sale |
6.42 |
12,824 |
82,330 |
265,354 |
| Matrix Capital Management Comp | 10% Owner |
May 07 '26 |
Sale |
5.64 |
6,922,870 |
39,044,987 |
0 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):